Latest Breaking News On - Nextcell pharma - Page 8 : comparemela.com

Diamyd Phase IIb trial results published in Diabetes Care STOCKHOLM, May 21, 2021 /PRNewswire/ Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical s lead drug candidate Diamyd (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd had a significant and positive effect on the preservation of insulin producing capacity in the predefined subgroup of individuals that carry the HLA DR3-DQ2 haplotype. In this subgroup of patients, more than 50% greater preservation of insulin producing capacity was observed at 15 months from baseline in those that received active treatment compared to placebo.

Czech republicUppsala lanMark atkinsonUlf hanneliusJohnny ludvigssonDiabetes research instituteUniversity of floridaCompany european phase iibUppsala university hospitalCompany certified adviserDiamyd medicalDiamyd medical boardProfessor johnny ludvigssonEuropean phaseUppsala universityNextcell pharma